EBMT 2022 | Achieving flawless CAR-T production: from apheresis to delivery
Bernd Eschgfaeller, PhD, Novartis Pharma AG, Basel, Switzerland, outlines the different factors that need to be taken into consideration to achieve optimal chimeric antigen receptor T-cell (CAR-T) production. To begin with, it is important to perform apheresis when the patient’s T-cell health is optimal, as it has been shown that T-cell fitness has an impact on manufacturing success and clinical outcomes. It is also essential to have a robust manufacturing process and a sufficient manufacturing capacity enabling the delivery of high-quality CAR-T products to the ever-increasing number of patients candidate for CAR-T therapy. Dr Eschgfaeller also talks on logistics in supply chain capabilities and the importance of the chain of identity (CoI) to ensure that cells can be tracked at any given time and that they belong to the right patient. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Full time employee of Novartis Pharma AG
